Susquehanna International Group
GALT icon

Susquehanna International Group’s Galectin Therapeutics GALT Stock Holding History

Susquehanna International Group’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.32M Sell
473,300
-42,300
-8% -$129K ﹤0.01% 7194
2025
Q4 		$2.14M Buy
515,600
+463,500
+890% +$2.44M ﹤0.01% 5513
2025
Q3 		$221K Sell
52,100
-1,200
-2% -$4.51K ﹤0.01% 10779
2025
Q2 		$112K Sell
53,300
-401,700
-88% -$601K ﹤0.01% 11713
2025
Q1 		$555K Sell
455,000
-887,800
-66% -$1.25M ﹤0.01% 8668
2024
Q4 		$1.73M Buy
1,342,800
+1,051,100
+360% +$2.52M ﹤0.01% 5633
2024
Q3 		$802K Sell
291,700
-676,400
-70% -$1.66M ﹤0.01% 7339
2024
Q2 		$2.19M Buy
968,100
+925,500
+2,173% +$2.81M ﹤0.01% 4934
2024
Q1 		$102K Buy
42,600
+28,200
+196% +$53.3K ﹤0.01% 11204
2023
Q4 		$23.9K Sell
14,400
-700
-5% -$1.36K ﹤0.01% 11936
2023
Q3 		$29K Sell
15,100
-23,000
-60% -$37.8K ﹤0.01% 11500
2023
Q2 		$54.9K Sell
38,100
-14,700
-28% -$24.9K ﹤0.01% 11300
2023
Q1 		$111K Sell
52,800
-14,900
-22% -$24.1K ﹤0.01% 11206
2022
Q4 		$76.5K Sell
67,700
-91,100
-57% -$121K ﹤0.01% 11167
2022
Q3 		$259K Buy
158,800
+49,200
+45% +$91.9K ﹤0.01% 10175
2022
Q2 		$144K Sell
109,600
-77,500
-41% -$111K ﹤0.01% 11078
2022
Q1 		$301K Buy
187,100
+42,300
+29% +$81.9K ﹤0.01% 10271
2021
Q4 		$300K Sell
144,800
-149,200
-51% -$426K ﹤0.01% 10496
2021
Q3 		$1.14M Buy
294,000
+204,600
+229% +$693K ﹤0.01% 7228
2021
Q2 		$286K Buy
89,400
+76,700
+604% +$273K ﹤0.01% 10860
2021
Q1 		$28K Sell
12,700
-43,200
-77% -$96.8K ﹤0.01% 12112
2020
Q4 		$125K Sell
55,900
-37,800
-40% -$99.2K ﹤0.01% 10370
2020
Q3 		$250K Buy
93,700
+50,200
+115% +$141K ﹤0.01% 9067
2020
Q2 		$133K Buy
43,500
+600
+1% +$1.51K ﹤0.01% 9344
2020
Q1 		$84K Buy
42,900
+1,100
+3% +$2.68K ﹤0.01% 9428
2019
Q4 		$120K Sell
41,800
-9,800
-19% -$34.1K ﹤0.01% 9055
2019
Q3 		$189K Sell
51,600
-66,300
-56% -$240K ﹤0.01% 9149
2019
Q2 		$489K Sell
117,900
-49,600
-30% -$215K ﹤0.01% 7311
2019
Q1 		$856K Sell
167,500
-42,700
-20% -$205K ﹤0.01% 5319
2018
Q4 		$721K Buy
210,200
+12,100
+6% +$57.8K ﹤0.01% 5328
2018
Q3 		$1.19M Buy
198,100
+141,300
+249% +$777K ﹤0.01% 4889
2018
Q2 		$361K Buy
56,800
+800
+1% +$3.9K ﹤0.01% 7474
2018
Q1 		$265K Sell
56,000
-2,100
-4% -$9.79K ﹤0.01% 7830
2017
Q4 		$194K Buy
58,100
+39,700
+216% +$100K ﹤0.01% 8303
2017
Q3 		$39K Sell
18,400
-28,600
-61% -$56.7K ﹤0.01% 8582
2017
Q2 		$116K Buy
47,000
+8,800
+23% +$23.4K ﹤0.01% 8616
2017
Q1 		$88K Sell
38,200
-5,600
-13% -$8.44K ﹤0.01% 8439
2016
Q4 		$43K Sell
43,800
-24,400
-36% -$21.7K ﹤0.01% 9321
2016
Q3 		$77K Buy
68,200
+47,700
+233% +$84.8K ﹤0.01% 8025
2016
Q2 		$30K Buy
20,500
+9,200
+81% +$13.5K ﹤0.01% 8326
2016
Q1 		$16K Buy
+11,300
New +$15.2K ﹤0.01% 8842
2015
Q2 		– Sell
-20,200
Closed -$68K – 10205
2015
Q1 		$68K Buy
+20,200
New +$72.2K ﹤0.01% 9083
2014
Q4 		– Sell
-45,800
Closed -$230K – 9762
2014
Q3 		$230K Sell
45,800
-30,700
-40% -$239K ﹤0.01% 8429
2014
Q2 		$1.06M Sell
76,500
-66,700
-47% -$830K ﹤0.01% 5940
2014
Q1 		$2.19M Buy
+143,200
New +$2.04M ﹤0.01% 4188

Other funds holding GALT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Susquehanna International Group's GALT Position: Q1 2026 in Review

Susquehanna International Group increased its Galectin Therapeutics (GALT) stake by 94% in Q1 2026, buying an estimated $818K and bringing the position to 555,702 shares worth $1.55M. The position accounts for ﹤0.01% of the portfolio, ranked #6791.

Susquehanna International Group first reported a position in GALT in Q4 2013 and has held it in 45 quarters since. The position peaked at $4.03M in Q1 2014. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

  • Susquehanna International Group held 555,702 shares of Galectin Therapeutics worth $1.55M as of Q1 2026.
  • Susquehanna International Group bought 268,783 Galectin Therapeutics shares in Q1 2026, an estimated $818K.
  • Galectin Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6791 holding.
  • Susquehanna International Group first reported a position in Galectin Therapeutics in Q4 2013 and has held it in 45 quarters since.
  • Susquehanna International Group's Galectin Therapeutics position peaked at $4.03M in Q1 2014.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.